☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Multiple Indications
Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications
April 5, 2021
Bayer Signs a Research and License Agreement with Curadev to Develop Novel STING Antagonists Across Multiple Indications
March 23, 2020
Merck Reports FDA's Acceptance of sBLA of Keytruda (pembrolizumab) with Six-Week Dosing Schedule for Multiple Indications
July 9, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.
